Cellular and molecular mechanisms of endothelial dysfunction in diabetes

Diabetes and Vascular Disease Research

Volumn 10, Issue 6, 2013, Pages 472-482

  Roberts, Anna C ^a   Porter, Karen E ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Diabetes; endothelial dysfunction; endothelial function; metabolic memory; microRNA; novel therapies

Indexed keywords

CELL ADHESION MOLECULE; CONNECTIVE TISSUE GROWTH FACTOR; DIACYLGLYCEROL; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN; FRACTALKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTACYCLIN; PROSTAGLANDIN H2; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C BETA; RANTES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THROMBOXANE A2; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANGIOGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DIABETES MELLITUS; DNA METHYLATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; EPIDEMIC; GLUCOSE HOMEOSTASIS; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; ISCHEMIC HEART DISEASE; MITOCHONDRIAL DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; REVIEW; RNA DEGRADATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

DIABETES; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL FUNCTION; METABOLIC MEMORY; MICRORNA; NOVEL THERAPIES;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EPIGENESIS, GENETIC; HOMEOSTASIS; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; OXIDATIVE STRESS; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84886068637     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164113500680     Document Type: Review

References (107)

1. Wang J, Luben R, Khaw K-T, et al. Dietary energy density predicts the risk of clinically incident type 2 diabetes: the EPIC-Norfolk study. Diabetes Care. 2008 ; 31: 2120-2125
2. Wilmot E, Edwardson C, Achana F, et al. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia. 2012 ; 55: 2895-2905
3. DiabetesUK. What is diabetes?http://www.diabetes.org.uk/Guide-to- diabetes/Introduction-to-diabetes/What-is-diabetes/ (accessed 17 October 2012).
4. International Diabetes Federation. Diabetes: a major risk factor. http://www.cvd.idf.org (accessed 17 October 2012).
5. Xu J, Zou M-H. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009 ; 120: 1266-1286
6. Feener EP, King GL. Endothelial dysfunction in diabetes mellitus: role in cardiovascular disease. Heart Fail Monit. 2001 ; 1: 74-82
7. Michiels C. Endothelial cell functions. J Cell Physiol. 2003 ; 196: 430-443
8. Levick JR An introduction to cardiovascular physiology. 4 th ed.London: Arnold Publishers, 2003. London: Arnold Publishers ; 2003
9. Yasa M, Turkseven S. Vasoprotective effects of nitric oxide in atherosclerosis. FABAD J Pharm Sci. 2005 ; 30: 41-53
10. Tronc F, Wassef M, Esposito B, et al. Role of NO in flow-induced remodeling of the rabbit common carotid artery. Arterioscler Thromb Vasc Biol. 1996 ; 16: 1256-1262
11. Gardiner SM, Compton AM, Bennett T, et al. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension. 1990 ; 15: 486-492
12. Rees DD, Palmer RMJ, Schulz R, et al. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 1990 ; 101: 746-752
13. Buga GM, Gold ME, Fukuto JM, et al. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension. 1991 ; 17: 187-193
14. Böhm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007 ; 76: 8-18
15. Varin R, Mulder P, Tamion F, et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure. Circulation. 2000 ; 102: 351-356
16. Tabit C, Chung W, Hamburg N, et al. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010 ; 11: 61-74
17. Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol. 2002 ; 34: 1508-1512
18. Förstermann U, Mügge A, Alheid U, et al. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res. 1988 ; 62: 185-190
19. Werns SW, Walton JA, Hsia HH, et al. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation. 1989 ; 79: 287-291
20. Bossaller C, Habib GB, Yamamoto H, et al. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5'-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest. 1987 ; 79: 170-174
21. Freiman PC, Mitchell GG, Heistad DD, et al. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res. 1986 ; 58: 783-789
22. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990 ; 81: 491-497
23. Widlansky ME, Gokce N, Keaney JJF, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003 ; 42: 1149-1160
24. McVeigh G, Brennan G, Johnston G, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1992 ; 35: 771-776
25. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium- dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993 ; 88: 2510-2516
26. Williams SB, Cusco JA, Roddy M-A, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996 ; 27: 567-574
27. Pasimeni G, Ribaudo MC, Capoccia D, et al. Non-invasive evaluation of endothelial dysfunction in uncomplicated obesity: relationship with insulin resistance. Microvasc Res. 2006 ; 71: 115-120
28. Steinberg H, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996 ; 97: 2601-2610
29. Hamburg NM, Larson MG, Vita JA, et al. Metabolic syndrome, insulin resistance, and brachial artery vasodilator function in Framingham offspring participants without clinical evidence of cardiovascular disease. Am J Cardiol. 2008 ; 101: 82-88
30. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo. Circulation. 2000 ; 101: 676-681
31. Montagnani M, Chen H, Barr VA, et al. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser1179. J Biol Chem. 2001 ; 276: 30392-30398
32. Ferri C, Pittoni V, Piccoli A, et al. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab. 1995 ; 80: 829-835
33. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006 ; 7: 85-96
34. Jiang ZY, Lin Y-W, Clemont A, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 1999 ; 104: 447-457
35. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000 ; 105: 311-320
36. Montagnani M, Golovchenko I, Kim I, et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem. 2002 ; 277: 1794-1799
37. Wheatcroft SB, Williams IL, Shah AM, et al. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 2003 ; 20: 255-268
38. Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001 ; 9: 414-417
39. Festa A, D'Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation. 2000 ; 102: 42-47
40. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013 ; 93: 137-188
41. Hotamisligil G, Shargill N, Spiegelman B. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993 ; 259: 87-91
42. Sethi JK, Hotamisligil GS. The role of TNFα in adipocyte metabolism. Semin Cell Dev Biol. 1999 ; 10: 19-29
43. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007 ; 3: 46-56
44. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-[alpha] function. Nature. 1997 ; 389: 610-614
45. Endocrine Today. TINSAL-T2D: salsalate lowered glucose in patients with type 2 diabetes, http://www.endocrinetoday.com/pda.aspx (accessed 12 November 2012).
46. Zhang J, Patel JM, Li YD, et al. Proinflammatory cytokines downregulate gene expression and activity of constitutive nitric oxide synthase in porcine pulmonary artery endothelial cells. Res Commun Mol Pathol Pharmacol. 1997 ; 96: 71-87
47. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008 ; 5: 338-349
48. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007 ; 87: 315-424
49. Sasaki N, Yamashita T, Takaya T, et al. Augmentation of vascular remodeling by uncoupled endothelial nitric oxide synthase in a mouse model of diabetes mellitus. Arterioscler Thromb Vasc Biol. 2008 ; 28: 1068-1076
50. Song P, Wu Y, Xu J, et al. Reactive nitrogen species induced by hyperglycemia suppresses Akt signaling and triggers apoptosis by upregulating phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) in an LKB1-dependent manner. Circulation. 2007 ; 116: 1585-1595
51. Nomiyama T, Igarashi Y, Taka H, et al. Reduction of insulin-stimulated glucose uptake by peroxynitrite is concurrent with tyrosine nitration of insulin receptor substrate-1. Biochem Biophys Res Commun. 2004 ; 320: 639-647
52. Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest. 2001 ; 108: 1341-1348
53. Shenouda SM, Widlansky ME, Chen K, et al. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation. 2011 ; 124: 444-453
54. Voinea M, Georgescu A, Manea A, et al. Superoxide dismutase entrapped-liposomes restore the impaired endothelium-dependent relaxation of resistance arteries in experimental diabetes. Eur J Pharmacol. 2004 ; 484: 111-118
55. Diederich D, Skopec J, Diederich A, et al. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol. 1994 ; 266: H1153 - H1161
56. Taddei S, Virdis A, Ghiadoni L, et al. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998 ; 97: 2222-2229
57. Ting HH, Timimi FK, Haley EA, et al. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation. 1997 ; 95: 2617-2622
58. Timimi FK, Ting HH, Haley EA, et al. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1998 ; 31: 552-557
59. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20â€̂536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 ; 360: 23-33
60. Lonn E, Yusuf S, Hoogwerf B, et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care. 2002 ; 25: 1919-1927
61. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 2007 ; 55: 498-510
62. Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol. 2005 ; 25: 487-496
63. Inoguchi T, Xia P, Kunisaki M, et al. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J Physiol. 1994 ; 267: E369 - E379
64. Mehta N, Sheetz M, Price K, et al. Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. Cardiovasc Drugs Ther. 2009 ; 23: 17-24
65. Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001 ; 88: e14 - e22
66. Beckman JA, Goldfine AB, Gordon MB, et al. Inhibition of protein kinase Cβ prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res. 2002 ; 90: 107-111
67. Beckman JA, Goldfine AB, Goldin A, et al. Inhibition of protein kinase Cβ does not improve endothelial function in type 2 diabetes. J Clin Endocrinol Metab. 2010 ; 95: 3783-3787
68. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001 ; 414: 813-820
69. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000 ; 404: 787-790
70. Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products. Circulation. 2006 ; 114: 597-605
71. Wautier M-P, Chappey O, Corda S, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001 ; 280: E685 - E694
72. Schmidt AM, Hori O, Brett J, et al. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994 ; 14: 1521-1528
73. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000 ; 342: 381-389
74. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 ; 353: 2643-2653
75. The epidemiology of Diabetes Interventions and Complications. Welcome to the EDIC study website, https://edic.bsc.gwu.edu/en (accessed 21 November 2012).
76. Roy S, Sala R, Cagliero E, et al. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci U S A. 1990 ; 87: 404-408
77. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes. 1987 ; 36: 808-812
78. Chan P-S, Kanwar M, Kowluru RA. Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. J Diabetes Complications. 2010 ; 24: 55-63
79. Reddy MA, Natarajan R. Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res. 2011 ; 90: 421-429
80. El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008 ; 205: 2409-2417
81. Brasacchio D, Okabe J, Tikellis C, et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009 ; 58: 1229-1236
82. Hiltunen MO, Turunen MP, Häkkinen TP, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med. 2002 ; 7: 5-11
83. Chan Y, Fish JE, D'Abreo C, et al. The cell-specific expression of endothelial nitric-oxide synthase: a role for DNA methylation. J Biol Chem. 2004 ; 279: 35087-35100
84. Fradin D, Bougnères P. T2DM: why epigenetics?. J Nutr Metab. 2011 ; 2011: 17
85. Jiang M, Zhang Y, Liu M, et al. Hypermethylation of hepatic glucokinase and L-type pyruvate kinase promoters in high-fat diet-induced obese rats. Endocrinology. 2011 ; 152: 1284-1289
86. Wang XH, Qian RZ, Zhang W, et al. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2009 ; 36: 181-188
87. Caporali A, Meloni M, Völlenkle C, et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation. 2011 ; 123: 282-291
88. Togliatto G, Trombetta A, Dentelli P, et al. MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose- and AGE-mediated vascular cell damage. Diabetologia. 2011 ; 54: 1930-1940
89. Liu X, Cheng Y, Yang J, et al. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol Cell Cardiol. 2012 ; 52: 245-255
90. Li Y, Song Y-H, Li F, et al. microRNA-221 regulates high glucose-induced endothelial dysfunction. Biochem Biophys Res Commun. 2009 ; 381: 81-83
91. Fang Y, Shi C, Manduchi E, et al. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A. 2010 ; 107: 13450-13455
92. Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008 ; 15: 272-284
93. Dentelli P, Rosso A, Orso F, et al. microRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression. Arterioscler Thromb Vasc Biol. 2010 ; 30: 1562-1568
94. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008 ; 15: 261-271
95. Fasanaro P, D'Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008 ; 283: 15878-15883
96. Sabatel C, Malvaux L, Bovy N, et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One. 2011 ; 6: e16979
97. Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res. 2012 ; 93: 583-593
98. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One. 2008 ; 3: e3148
99. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010 ; 107: 810-817
100. Look AHEAD (Action for Health in Diabetes). Look AHEAD, https://www.lookaheadtrial.org/public/home.cfm (accessed 23 November 2012).
101. US Department of Health and Human Services. Weight loss does not lower heart disease risk from type 2 diabetes, http://www.nih.gov/news/health/oct2012/ niddk-19.htm (accessed 23 November 2012).
102. Cuny T, Guerci B, Cariou B. New avenues for the pharmacological management of type 2 diabetes: an update. Ann Endocrinol. 2012 ; 73: 459-468
103. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008 ; 168: 2070-2080
104. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010 ; 33: 1389-1394
105. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010 ; 170: 1191-1201
106. Yamakuchi M. MicroRNAs in vascular biology. Int J Vasc Med. 2012 ; 2012: 794898
107. Madi HA, Riches K, Warburton P, et al. Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and type 2 diabetic patients. Am J Physiol Cell Physiol. 2009 ; 297: C1307 - C1317